OncoMatch/Clinical Trials/NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Is NCT06119685 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for nhl.
Treatment: IDP-023 · Rituximab · Daratumumab · Interleukin-2 · Cyclophosphamide · Fludarabine · Mesna · Isatuximab — This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Impaired cardiac function or history of clinically significant cardiac disease [excluded]
Impaired cardiac function or history of clinical significant cardiac disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Valkyrie Clinical Trials · Los Angeles, California
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center · Lake Mary, Florida
- Emory University Hospital · Atlanta, Georgia
- University of Minnesota · Minneapolis, Minnesota
- NYP/Weill Cornell Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify